References
- Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2015;35:725–734.
- Gil MM, Accurti V, Santacruz B, et al. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017;50:302–314.
- Kagan KO, Wright D, Etchegaray A, et al. Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol. 2009;33:657–664.
- Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med. 2005;353:2001–2011.
- Canick JA, Palomaki GE, Kloza EM, et al. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn. 2013;33:667–674.
- Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372:1589–1597.
- Thornburg LL, Mulconry M, Post A, et al. Fetal nuchal translucency thickness evaluation in the overweight and obese gravida. Ultrasound Obstet Gynecol. 2009;33:665–669.
- Wang E, Batey A, Struble C, et al. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013;33:662–666.
- Ashoor G, Poon L, Syngelaki A, et al. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: effect of maternal and fetal factors. Fetal Diagn Ther. 2012;31:237–243.
- Dar P, Curnow KJ, Gross SJ, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol. 2014;211:527.e1–527.e17.
- Kinnings SL, Geis JA, Almasri E, et al. Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing. Prenat Diagn. 2015;35:816–822.
- Revello R, Sarno L, Ispas A, et al. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result. Ultrasound Obstet Gynecol. 2016;47:698–704.
- Benn P, Valenti E, Shah S, et al. Factors associated with informative redraw after an initial no result in noninvasive prenatal testing. Obstet Gynecol. 2018;132:428–435.
- Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18:1056–1065.
- Sarno L, Revello R, Hanson E, et al. Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy. Ultrasound Obstet Gynecol. 2016;47:705–711.
- Lee TJ, Rolnik DL, Menezes MA, et al. Cell-free fetal DNA testing in singleton IVF conceptions. Hum Reprod. 2018;33:572–578.
- Sparks AB, Struble CA, Wang ET, et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;206:319.e1–319.e9.
- Juneau K, Bogard PE, Huang S, et al. Microarray-based cell-free DNA analysis improves noninvasive prenatal testing. Fetal Diagn Ther. 2014;36:282–286.
- Schmid M, White K, Stokowski R, et al. Accuracy and reproducibility of fetal-fraction measurement using relative quantitation at polymorphic loci with microarray. Ultrasound Obstet Gynecol. 2018;51:813–817.
- R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available from: https://www.R-project.org.
- Livergood MC, Lechien KA, Trudell AS. Obesity and cell-free DNA “No Calls”: is there an optimal gestational age at time of sampling? Am J Obstet Gynecol. 2017;216:413.e1–413.e9.
- Langlois S, Johnson J, Audibert F, et al. Comparison of first-tier cell-free DNA screening for common aneuploidies with conventional publically funded screening. Prenat Diagn. 2017;37:1238–1244.